NCT02327689

Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Asian-Pacific Alliance of Liver Disease, Beijing · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV related cirrhosis patients. Patients were divided into 2 groups: compensated HBV related cirrhosis patients and decompensated HBV related cirrhosis patients.

Detailed description

Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB) patients in China. Yet data are limited for this agent plus adefovir dipivoxil in cirrhosis patients. The investigators design this trial to test the effect of FTC plus adefovir dipivoxil in Chinese naive compensated and decompensated HBV related cirrhosis patients.

Conditions

• Hepatitis B, Chronic
• Fibrosis

Interventions

Type	Name	Description
DRUG	Emtricitabine plus adefovir dipivoxil	emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-07-01
• Completion: 2017-07-01
• First posted: 2014-12-30
• Last updated: 2014-12-30